Stay updated with breaking news from Abrocitinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai. ....
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference. ....
The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023. ....
CHMP also recommends XELJANZ (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's ....
NEW YORK CITY (dpa-AFX) - The European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the 100 mg and 200 mg doses of ....